Tuesday 21 February 2017

Turing Pharma is looking to replace vilified ex-CEO Martin Shkreli

Ankush Sharma

Published 23/12/2015 | 07:40

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals

Turing Pharmaceuticals has said it is seeking a new chief executive to replace Martin Shkreli, the price-gouging entrepreneur who is facing US charges of securities fraud, and will cut jobs in a restructuring.

  • Go To

The private Swiss-based company will also expand its board to include new, independent members, it added.

Shkreli, 32, resigned as CEO on Friday, a day after his arrest on charges that he had engaged in a Ponzi-like scheme. He pleaded not guilty and was released on $5 million bail.

On Monday, KaloBios Pharmaceuticals said Shkreli was "terminated" as CEO and had resigned from the board.

Turing did not specify the number of job cuts in a statement. It could not be immediately reached for comment.

"These staff changes put us in the best position to continue executing on our long-term plan," said Chairman and Interim Chief Executive Ron Tilles, who took over Shkreli's job on Friday.

Shkreli gained notoriety when, as Turing's CEO, he raised the price of a life saving drug overnight to $750 from $13.50.

Reuters

Read More

Promoted articles

Editors Choice

Also in Business